Form 13-F position report

PROTAGONIST THERAPEUTICS INC

Reported by EAM Investors LLC

PTGX CUSIP 74366E102 Manager CIK 0001510989

Reported 53,595 shares, up 26,104 (95.0%) from the prior quarter.

Reported value 124.1%; share count 95.0% vs. the prior quarter.

Added
% of reported 13F value 0.78% This manager · Q3 2026
Shares 53,595 Quarter-end amount reported
Reported value $7,551,000 Fair value at quarter end
Consecutive quarters held 7 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 2429262
2023-09-30 0
2025-03-31 3345593
2025-06-30 3977837
2025-09-30 5232953
2025-12-31 6856015
2026-03-31 2942136
2026-06-30 3369847
2026-09-30 7551000

Quarterly position history

How this manager's reported quarter-end position changed over time.

9 quarters
Quarterly reported position history for PROTAGONIST THERAPEUTICS INC held by EAM Investors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 53,595 +26,104 (95.0%) 0.78% $7,551,000 2026-11-16
Q2 2026 Reduced 27,491 -423 (-1.5%) 0.3% $3,369,847 2026-08-13
Q1 2026 Reduced 27,914 -50,584 (-64.4%) 0.34% $2,942,136 2026-05-13
Q4 2025 Reduced 78,498 -1,569 (-2.0%) 0.76% $6,856,015 2026-02-12
Q3 2025 Added 80,067 +8,096 (11.2%) 0.6% $5,232,953 2025-11-14
Q2 2025 Added 71,971 +2,790 (4.0%) 0.6% $3,977,837 2025-08-12
Q1 2025 New 69,181 +69,181 (0.0%) 0.58% $3,345,593 2025-05-13
Q3 2023 Reduced 0 -87,953 (-100.0%) 0 $0 2023-11-13
Q2 2023 New 87,953 +87,953 (0.0%) 0.45% $2,429,262 2023-08-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

419 managers reported PROTAGONIST THERAPEUTICS INC for Q3 2026.

Managers reporting PROTAGONIST THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 10,734,300 +426,463 0.02% $1,512,355,549 9 qtrs
FARALLON CAPITAL MANAGEMENT LLC Added 6,437,906 +89,000 3.91% $907,036,576 36 qtrs
RTW INVESTMENTS LP Unchanged 5,061,175 0 7.19% $713,068,946 29 qtrs
UBS Group AG Added 3,953,236 +554,015 0.07% $556,971,420 41 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 3,668,478 +39,180 0.02% $516,851,865 3 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 3,543,702 +126,921 0.09% $499,272,174 9 qtrs
STATE STREET CORPORATION Added 3,479,267 +157,713 0.01% $490,193,928 41 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 2,895,169 +41,775 < 0.01% $407,900,360 3 qtrs
Invesco Ltd Added 2,837,318 +496,651 0.03% $399,749,732 31 qtrs
JOHNSON & JOHNSON Unchanged 2,449,183 0 45.3% $345,065,393 21 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
Common Stock

Voting authority reported

Sole
11,574
Shared
0
None
42,021

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.